BioXcel Therapeutics Files Chapter 11, Lines Up $125M Teva Asset Sale
BioXcel Therapeutics filed chapter 11 in Delaware to pursue a court-supervised asset sale. Teva is the proposed stalking-horse buyer, offering $57.5M in cash plus up to $67.5M in milestones; BioXcel also seeks up to $19M in debtor-in-possession financing.